Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As you can imagine, this is a great benefit to those who face mobility challenges |
| The results were truly remarkable |
| It was a busy quarter for us at Helius, and we're excited about what we accomplished and the road ahead |
| We are starting to see traction with the exclusive distribution agreement with HealthTech Connex for portions of Western Canada that we signed at the end of the first quarter and expect steady overall growth to continue |
| The fact that these 2 institutions committed to purchase PoNS reflects the medical community's strong desire to improve treatment for this patient population, and we believe that evidence from the treatment outcome will support healthy economic benefit and cost effectiveness of incorporating PoNS therapy as a first-line treatment for stroke patients |
| These are exciting opportunities and both come about due to the body of clinical evidence demonstrating the effectiveness of using PoNS to treat stroke |
| While we don't know the outcome of this bipartisan piece of legislation, we are optimistic about its potential and the fact it provides another pathway toward reimbursement and greater access for patients |
| Earlier this week, we were proud to announce the results of a study performed by Pacific Blue Cross and HealthTech Connex with the ultimate goal of reducing long-term disability and improving the quality of life for individuals suffering from traumatic brain injury in Canada, where PoNS is authorized to treat TBI |
| We're living in very exciting times for PoNS Therapy |
| We are pleased to report that virtually all the prescriptions in the United States are now fulfilled through UpScript |
| So we've had a great relationship with them for a number of years |
| We began the quarter with the conclusion of our very successful Patient Therapy Access Program, which we launched in June 2022 to give qualified Americans, suffering from balance and gait impairment due to MS, the ability to purchase PoNS at a significantly reduced price |
| The data from these clinical application trials will also provide supporting evidence of PoNS therapeutic benefit that can strengthen the registrational program for stroke currently ongoing in the U.S |
| We believe the findings from this collaboration may promote our efforts to gain reimbursement by Canadian insurance companies and health care providers as well as demonstrating the PoNS Therapy's significant health economic benefit and cost effectiveness as we negotiate coverage with U.S |
| Revenues in Canada were $72,000 during the quarter, up 29% over the third quarter of last year |
| In addition to significant improvements in balance and gait, patients reported improvement in headache severity as well as in cognitive and mental health symptoms |
| But they're also happy to see Quebec being the first one stepping in to do this balance and gait study in stroke |
| We continue to believe that broad third-party payer reimbursement is needed to achieve our full revenue potential, and I'm pleased to report, we're moving closer to that goal |
| But in general, we have a great relationship with them |
| Furthermore, this evidence should provide valuable benchmark for other Canadian health care providers and private payers as they evaluate reimbursement of PoNS Therapy |
| Stroke patients experienced a significant improvement in gait, averaging a 6.74 point improvement in the Functional Gait Assessment score over the 14-week treatment period |
| And in each site, the goal is five to 15 patients per site to get us in the 50 patients for the total research trial that we deem is very valuable to bring all these KOLs in to expand mindshare and really get experience treating their MS patients with PoNS |
| It was also found that PoNS Therapy reduced the financial burden to the insurance provided by at least $1.6 million for the 5 individuals who returned to work for nearly a 10x savings on cost |
| Those are just wonderful things to see with using PoNS Therapy as hopefully a standard of care going forward in treating traumatic brain injuries |
| The implementation of PTAP enabled us to accomplish 2 key objectives |
| With our continued focus on cash management and a runway that will take us into the second quarter of 2024, we have both the drive and resources necessary to continue pushing forward and bringing our life-changing therapy to as many patients as possible |
| Awesome |
| Awesome |
| If and when PoNS is approved to treat stroke in the U.S., it will be eligible for coverage under the proposed Transitional Coverage of Emerging Technologies or TCET pathway, which would expedite Medicare coverage of certain breakthrough devices by allowing manufacturers the opportunity for increased premarket engagement with CMS |
| So our belief is those eight out of nine, actually, in 89% of the study, we felt like we met the goal of the ability to go back to work |
| Statement |
|---|
| Total revenue for the third quarter of 2023 was $143,000, a decrease of $53,000 compared to $196,000 in the third quarter of 2022, primarily attributable to the decreased unit sales of PoNS systems in the U.S |
| Rehabilitation therapy is the current standard of care, but its return to work rate is very low |
| decreased following the expiration of the PTAP program on June 30 as sales of PoNS Systems reverted to the cash-pay price |
| Operating loss for the third quarter of 2023 was $3.2 million compared to a loss of $4.9 million for the prior year period |
| It's a bit confusing |
| We reported a net loss for the third quarter of 2023 of $3.7 million or a loss of $5.49 per basic and diluted common share compared to a net loss of $1 million or a loss of $2.90 per basic and diluted common share for the same period last year |
| And remember, these patients were deemed unlikely to resume their jobs |
| So some of those were a little confusing in that publication |
| Selling, general and administrative expense for the third quarter of 2023 was $2.2 million, a decrease of $1.2 million compared to $3.4 million in the third quarter of 2022, primarily the result of a decrease in performance-based stock compensation expense |
| As expected, quarterly sales of PoNS Systems in the U.S |
Please consider a small donation if you think this website provides you with relevant information